BIOCRYST PHARMACEUTICALS, INC.
Last · —$8.05-0.02 (-0.25%)live · yahoo · 1h ago
Market cap$2.06B—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $940.6M |
|---|---|
| Operating income | $-313.2M |
| Net income | $-384.7M |
| Free cash flow | $373.4M |
| Operating margin | -33.3% |
| Net margin | -40.9% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2025-02-25
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Medium
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -19.7%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -11.5%
- Cash Runway Medium — Cash runway ~2.0 years
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$0.12
Est. revenue
165.7M
Earnings transcripts
Press & signals
- GlobeNewswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
- GlobeNewswire
BioCryst Reports Second Quarter 2026 Financial Results
- Satelight
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans